FOLH1 and neoplasm: Early clinical studies have shown that over 60% of HRPCa patients exhibit substantial intraprostatic tumor shrinkage on PET following ADT and that residual PSMA-PET after 3 months of nADT correlated to the extent of histopathology response at surgery [5,14].